OnKure CEO granted 330,000 stock options
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of employee stock options covering 330,000 shares of Class A Common Stock.
Rhea-AI Filing Summary
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of employee stock options covering 330,000 shares of Class A Common Stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.
According to the filing, Saccomano holds 330,000 options following this grant, all as direct holdings. The award vests over time, with 1/48th of the option shares vesting on May 1, 2026 and monthly thereafter, contingent on his continued service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 330,000 shares
Grant/Award
1 txn
Insider
Saccomano Nicholas A
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 330,000 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 330,000 contracts (Direct)
Footnotes (1)
- F1. 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Key Figures
Option grant size: 330,000 options
Exercise price: $4.07 per share
Expiration date: March 31, 2036
+2 more
5 metrics
Option grant size
330,000 options
Employee stock option grant to CEO for Class A Common Stock
Exercise price
$4.07 per share
Exercise price of employee stock option grant
Expiration date
March 31, 2036
Option expiration date for CEO grant
Post-grant derivative holdings
330,000 options
Total options held following the reported transaction
Initial vesting date fraction
1/48th on May 1, 2026
First vesting installment of CEO option grant
Key Terms
Employee Stock Option, exercise price, vesting, Class A Common Stock, +1 more
5 terms
Employee Stock Option financial
"security_title: "Employee Stock Option (right to buy)""
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
exercise price financial
"conversion_or_exercise_price: "4.0700" per share as the exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/48th of the shares subject to the option shall vest on May 1, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Class A Common Stock financial
"underlying_security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did OnKure Therapeutics (OKUR) disclose for Nicholas Saccomano?
OnKure Therapeutics disclosed that President and CEO Nicholas A. Saccomano received a grant of employee stock options for 330,000 shares of Class A Common Stock. These options were awarded as compensation and are not an open-market stock purchase or sale.
What are the key terms of Nicholas Saccomano’s new stock options at OnKure (OKUR)?
The granted employee stock options cover 330,000 underlying Class A Common Stock shares at an exercise price of $4.07 per share. They expire on March 31, 2036, giving Saccomano the right to buy shares at that price before expiration, subject to vesting.
How do Nicholas Saccomano’s OnKure (OKUR) options vest over time?
The filing states that 1/48th of the option shares will vest on May 1, 2026, with additional installments vesting each month thereafter. Vesting continues only if Saccomano remains a service provider to OnKure through each scheduled vesting date, making it time-based compensation.
How many options does Nicholas Saccomano hold after this OnKure (OKUR) grant?
After this grant, Saccomano holds 330,000 employee stock options directly, as reported in the filing. All these options relate to Class A Common Stock and reflect his total option position shown, indicating this award establishes his reported derivative holdings in the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
